Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.82
38.06
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Capital Expenditures
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
|
Capital Expenditures
-¥113.1m
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-4%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Capital Expenditures
-¥219.6m
|
CAGR 3-Years
46%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Capital Expenditures
-¥103.9m
|
CAGR 3-Years
37%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
4%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Capital Expenditures
-¥1.6B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-23%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Capital Expenditures
-¥548.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-27%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Capital Expenditures
-¥81.9m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Glance View
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. engages in the research, development, processing, wholesale, retail, and manufacturing of Chinese herbal medicines, Chinese patent medicines, Chinese medicine decoction tablets, western medicine preparations, and other medical and health products. The company is headquartered in Tianjin, Tianjin and currently employs 4,650 full-time employees. The company went IPO on 2001-06-06. The firm's businesses cover the whole industry chain of traditional Chinese medicine, including the cultivation of Chinese medicinal materials, trade of Chinese medicinal materials, research and development (R&D), production and sales of Chinese patent medicines, production and sales of Chinese herbal decoction pieces, pharmaceutical commercial logistics, pharmaceutical retailing, chemical raw materials and preparations, biomedicine and many other fields. The firm's products include cardiovascular and cerebrovascular medicines, respiratory medicines, spleen and stomach medicines, cold medicines, oncology medicines, gynecological medicines, pediatric medicines and other other product groups.
See Also
What is Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Capital Expenditures?
Capital Expenditures
-113.1m
CNY
Based on the financial report for Jun 30, 2024, Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Capital Expenditures amounts to -113.1m CNY.
What is Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-4%
Over the last year, the Capital Expenditures growth was 5%. The average annual Capital Expenditures growth rates for Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd have been 12% over the past three years , 9% over the past five years , and -4% over the past ten years .
You don't have any saved screeners yet
